2
Clinical Trials associated with HNC364 / Not yet recruitingPhase 1 A Relative Bioavailability Study of HNC364 Following Intramuscular Injections Vs. AZILECT® (Rasagiline Tablet) Following Oral Administration At the Steady-State in Healthy Adult Subjects
HNC364 is a new pro-drug of rasagiline as a long-acting injection for deep IM deltoid injection, for the treatment of Parkinson"s disease (PD). As a pro-drug of rasagiline, HNC364 will readily and completely convert to rasagiline after the IM administration.
This is a non-randomized, open-label, Phase 1 study to evaluate the relative bioavailability of HNC364 injectable suspension relative to AZILECT® (rasagiline tablets), to assess the safety and tolerability of multiple IM dose HNC364 injectable suspension dose administration in healthy adult subjects.
Phase 1, Non-randomized, Single Ascending Doses (SAD) Study Following Single Injection in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
100 Clinical Results associated with HNC364
100 Translational Medicine associated with HNC364
100 Patents (Medical) associated with HNC364
100 Deals associated with HNC364